

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly L. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shawn DeFrees

Application No.: 10/658,823

Filed: September 8, 2003

For: GLYCOSYLTRANSFERASE  
INHIBITORS

Confirmation No.: 2850

Examiner: Hanley, Susan Marie

Art Unit: 1651

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The additional references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of a European Examination Report dated April 26, 2006, which was issued in corresponding European application no. 00936281.5, and in which these references were cited.


As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, because this submission is prior to the issuance of a first Office Action on the merits.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Kenneth E. Jenkins  
Reg. No. 51,846

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 858-350-6100  
Fax: 415-576-0300  
KEJ:tsp  
60777391 v1

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				10/858,823	
				Filing Date	
				September 8, 2003	
				First Named Inventor	
DeFrees, Ph.D., Shawn					
Art Unit		1651			
Examiner Name		Hanley, Susan Marie			
Attorney Docket Number		020014-013911US			
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	BA	ICHIKAWA, Yoshitaka, et al. "Chemical-Enzymatic Synthesis and Conformational Analysis of Sialyl Lewis x and Derivatives", <i>J. Am. Chem. Soc.</i> (1992) 114:9283-9298	<input type="checkbox"/>	
	BB	WONG, Chi-Huey, et al. "Specificity, Inhibition and Synthetic Utility of a Recombinant Human $\alpha$ -1,3, Fucosyltransferase", <i>J. Am. Chem. Soc.</i> (1992) 114:7231-7322	<input type="checkbox"/>	
	BC	QIAO, Lei, et al. "Synergistic Inhibition of Human $\alpha$ -1,3, Fucosyltransferase V", <i>J. Am. Chem. Soc.</i> (1996) 118:7653-7662	<input type="checkbox"/>	
	BD	CHATTERJEE, Subroto, "Oxidized low density lipoproteins and lectosylceramide both stimulate the expression of proliferating cell nuclear antigen and the proliferation of aortic smooth muscle cells", <i>Indian Journal of Biochemistry &amp; Biophysics</i> , (1997) 34:58-80	<input type="checkbox"/>	
	BE	TAKAYAMA, Suichi, et al. "Selective Inhibition of $\beta$ -1,4- and $\alpha$ -1,3-Galactosyltransferases: Donor Sugar-Nucleotide Based Approach", <i>Bioorganic &amp; Medicinal Chemistry</i> (1999) 7:401-409	<input type="checkbox"/>	
	BF	BROQUET, Pierre, et al. "Effect of Desipramine on a Glycoprotein Sialyltransferase Activity in C8 Cultured Glioma Cells", <i>Journal of Neurochemistry</i> , (1990) 54(2):388-394	<input type="checkbox"/>	
	BG		<input type="checkbox"/>	
	BH		<input type="checkbox"/>	
	BI		<input type="checkbox"/>	
	BJ		<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language translation is attached.